A new study published in the BMJ has found that at least 24% of metal-on-metal hip replacements have not been researched to adequately prove clinical effectiveness. The study also shows that 8% of those implanted in 2011 had no clinical study proving effectiveness.
BioMet is one of the several manufacturers who have come under fire for their metal-on-metal hip implants. The BioMet M2a Magnum hip replacement has been found to cause severe complications among hip implant patients.
A 2011 study in the Australian National Joint Registry found that 7.2% of M2a Magnum hip replacements fail and require revision surgery within a year, a rate much higher than normal. Metal hip implant side effects include tissue damage, loosening of the hip, limited mobility and toxic levels of metal in the bloodstream.